Acute Myeloid Leukemia (AML) is a difficult to treat cancer that starts in the bone marrow and then moves quickly into the blood allowing it to spread to other parts of the body including the lymph nodes, liver, spleen, and central nervous system. Despite progress in the treatment of AML, the clinical outcome remains low […]

This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of Temozolomide (TMZ) and Perillyl Alcohol (POH), has been shown to provide a method of providing chemotherapeutic treatment of brain-based-glioblastomas than the current TMZ-only therapy courses alone. In the study, NeOnc Technologies used mass […]

A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow or stop the formation of Glioblastoma Tumors suggests additional benefits over TMZ treatment alone. For those with Glioblastoma (GB) brain cancer, the survival prognosis is […]

NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key processes in cancer tumor growth. In tumor cells, the endothelial-to-mesenchymal transition (EndMT) supports the pro-angiogenic and invasive characteristics of glioblastoma multiforme (GBM). Blocking this process would be a promising approach to inhibit tumor […]

Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is associated with high recurrence, and resistance to the current standard of care chemotherapy, temozolomide (TMZ). Despite great progress made in surgery and therapies, there has […]

In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal carcinoma (NPC) could inhibit NPC cell proliferation, and cause G2/M arrest and DNA damage. NEO212 is Neonc’s patented conjugated formulation of Temozolomide with Neonc’s highly purified Perillyl Alcohol. Temozolomide is a chemotherapy drug used primarily to treat […]